Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update.
PubMedPublished 28 October 2003Open access
Jacques Genest, Jiří Fröhlich, George Fodor, Ruth McPherson
Citations346
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Challenges in Canada, as in all industrialized countries, include the increasing size of the elderly population and the rising prevalence of obesity and diabetes mellitus.
Keywords
MedicineEconomics, Econometrics and Finance
JAMASummary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
27,886 Citations1993Scott M. Grundy
Dairy therapy remains the first line of treatment of high blood cholesterol, and drug therapy is reserved for patients who are considered to be at high risk for CHD, and the fundamental approach to treatment is comparable.
The LancetMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
6,967 Citations2002S. Féasson
Adding simvastatin to existing treatments safely produces substantial additional benefits for a wide range of high-risk patients, irrespective of their initial cholesterol concentrations.
JAMAEffects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes<SUBTITLE>The MIRACL Study: A Randomized Controlled Trial</SUBTITLE>
2,493 Citations2001Gregory G. Schwartz
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes and the MIRACL study are studied.
CirculationAssessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations
1,312 Citations1999Scott M. Grundy, Richard C. Pasternak +3 more
The approaches described in this statement can be used for guidance at several levels of primary prevention; however, the statement does not attempt to specifically link risk assessment to treatment guidelines for particular risk factors, but provides critical background information that could be used in the development of new treatment guidelines.
PubMedRecommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.
188 Citations2000J Fodor, JJ Frohlich +2 more
Despite the steady decline in the rate of death from coronary artery disease during the past 25 years, cardiovascular disease remains the leading cause of death in Canada, accounting for 37% of total deaths.